We are ChemPartner, an innovative, full-service life science CRO/CDMO providing biopharmaceutical research with a global reach. We have evolved from a chemistry service provider to a company offering full-service drug discovery and development for both small and large molecules, supported by biology, pharmacology, DMPK, and exploratory toxicology.
We are dedicated to technically and strategically accomplishing the research initiatives of pharmaceutical and biotech companies worldwide. Our mission is to provide clients with the highest quality R&D services in a timely and cost-effective manner.
As a Contract Research Organization (CRO) ChemPartner has helped hundreds of clients take their small molecule and biologics projects from all stages of drug discovery to pre-clinical candidate selection and beyond. We provide assistance not only in laboratory settings but also intellectual input at various levels, such as project strategy, experimental study design, data interpretation, and source reports for regulatory filings.
As a Contract Development and Manufacturing Organization (CDMO), we offer pharmaceutical development and manufacturing services for small molecules and biologics. We provide one-stop services for overall process development and IND application support, with a quality system in compliance with ICH guidelines and the highest standards of the CFDA, FDA, and EMA. We have expanded our Biologics GMP manufacturing capacity in our new facility in Qidong, suitable for commercial drug substance or products.
ChemPartner is uniquely positioned to not only be a CRO/CDMO, but to be the most reliable pharmaceutical alliance partner providing intellectual contributions and exceptional technical expertise.
We are dedicated to technically and strategically accomplishing the research initiatives of pharmaceutical and biotech companies worldwide. Our mission is to provide clients with the highest quality R&D services in a timely and cost-effective manner.
As a Contract Research Organization (CRO) ChemPartner has helped hundreds of clients take their small molecule and biologics projects from all stages of drug discovery to pre-clinical candidate selection and beyond. We provide assistance not only in laboratory settings but also intellectual input at various levels, such as project strategy, experimental study design, data interpretation, and source reports for regulatory filings.
As a Contract Development and Manufacturing Organization (CDMO), we offer pharmaceutical development and manufacturing services for small molecules and biologics. We provide one-stop services for overall process development and IND application support, with a quality system in compliance with ICH guidelines and the highest standards of the CFDA, FDA, and EMA. We have expanded our Biologics GMP manufacturing capacity in our new facility in Qidong, suitable for commercial drug substance or products.
ChemPartner is uniquely positioned to not only be a CRO/CDMO, but to be the most reliable pharmaceutical alliance partner providing intellectual contributions and exceptional technical expertise.
Location: China, Shanghai
Employees: 1001-5000
Founded date: 2002
Mentions in press and media 8
| Date | Title | Description |
| 21.06.2023 | Dr. Yinfei Yin Joins Shanghai ChemPartner as Vice President and Head of Biology and Pharmacology | SHANGHAI, June 21, 2023 /PRNewswire/ -- ChemPartner announced today the appointment of Yinfei Yin, Ph.D. as vice president of and head of the biology and pharmacology department at Shanghai ChemPartner. Dr. Yin brings a wealth of experience... |
| 24.02.2023 | Dr. Lilly Xu Named President of Shanghai ChemPartner | SHANGHAI, Feb. 24, 2023 /PRNewswire/ -- ChemPartner announced today the appointment of Lilly Xu, Ph.D. as President of Shanghai ChemPartner. Dr. Xu is a seasoned manager with a strong portfolio of success. She joined ChemPartner in 2017 to ... |
| 29.09.2022 | Biological Macromolecules: Exploring Analytical Development and QC Case Studies in Antibody Developability and Biologics CMC, Upcoming Webinar Hosted by Xtalks | A developability assessment at an early stage can provide a better understanding of candidates, deliver better and safer therapeutic candidates and reduce risk during late-stage development. TORONTO (PRWEB) September 29, 2022 Biological mac... |
| 06.11.2019 | Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor | CAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 — Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announce the in-li... |
| 05.08.2019 | How Biotech Startup Funding Will Change in the Next 10 Years | Back when YC was getting started about 10 years ago, Paul Graham wrote some essays that predicted the way startup fundraising would change in the next decade – accurately, it turns out. Paul Graham predicted that there would be way more sta... |
| - | The Scripps Research Institute and ShangPharma Innovation Announce Translational Research Collaboration | La Jolla, California (June 8, 2017) – The Scripps Research Institute (TSRI) and ShangPharma Innovation, Inc. (SPII) today announced a strategic collaboration to accelerate the development of innovative drug candidates through scientific col... |
| - | ShangPharma Innovation Expands Incubator to Drive Life Science Innovation in Bay Area | SOUTH SAN FRANCISCO, California, March 19, 2018 — ShangPharma Innovation Inc., a global venture capital firm focused on filling the critical investment gap that exists for the earliest-stage therapeutic breakthroughs, has expanded its life ... |
| - | How Biotech Startup Funding Will Change in the Next 10 Years | Back when YC was getting started about 10 years ago, Paul Graham wrote some essays that predicted the way startup fundraising would change in the next decade - accurately, it turns out. Paul Graham predicted that there would be way more sta... |